* Silk Road Medical Inc SILK.OQ SILK.O is expected
to show a
rise in quarterly revenue when it reports results on July 26.
* The Sunnyvale California-based company is expected to
report a
17.3% increase in revenue to $31.027 million from $26.46 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Silk Road Medical
Inc is
for a loss of 46 cents per share. For the same quarter last
year, the company reported a loss of 31 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Silk Road
Medical
Inc is $43, above its last closing price of $41.51.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.40 -0.37 -0.48 Missed -29.1
Dec. 31 2022 -0.37 -0.36 -0.42 Missed -17.6
Sep. 30 2021 -0.30 -0.30 -0.40 Missed -32.9
Jun. 30 2021 -0.36 -0.37 -0.31 Beat 15.1
Mar. -0.42 -0.39 -0.31 Beat 20.7
31 2021
Dec. 31 2020 -0.27 -0.28 -0.49 Missed -75.3
Sep. 30 2020 -0.29 -0.29 -0.31 Missed -8.7
Jun. 30 2020 -0.37 -0.37 -0.32 Beat 13.2
This summary was machine generated July 23 at 00:23 GMT. All
figures in US dollars unless otherwise stated